The Quantellect read.As of Nov 19, 2026, 7 active firms cover Neumora Therapeutics, Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $4.00 to $14.00 (about 3.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $7.17 sits 1884% above the current $0.36. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.17
+1883.6% upside
Average target across 6 active firms as of Nov 19, 2026 vs $0.36 current
Highest Target$14.00
Average Target$7.17
Lowest Target$4.00
Detailed analyst forecasts for NMRA
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate NMRA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NMRA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.20 – $-0.13 · 7 analysts · -51% YoY
Next period, 7 analysts expect Neumora Therapeutics, Inc. to earn $-0.17 a share (range $-0.20 – $-0.13), versus $-0.35 a year earlier. Full-year consensus is $-0.86, growing to $-0.61 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Neumora Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NMRA.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$14.00+3774.9% to target
Overall win rate
50%
+ Follow
#2
Ami Fadia
Needham · Rank #92
Buy
$5.00+1283.9% to target
Overall win rate
46%
+ Follow
#3
Graig Suvannavejh
Mizuho · Rank #239
Buy
$4.00+1007.1% to target
Overall win rate
40%
+ Follow
#4
Marc Goodman
Leerink Partners · Rank #251
Buy
$8.00+2114.2% to target
Overall win rate
46%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #312
Buy
$7.00+1837.4% to target
Overall win rate
35%
+ Follow
NMRA stock forecast FAQ
What is NMRA's average 12-month price target?+
The 6 active firms with a live target average $7.17 for Neumora Therapeutics, Inc. over the next 12 months, ranging from a $14.00 high to a $4.00 low, as of Nov 19, 2026.
Is NMRA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NMRA?+
The Street-high target is $14.00 (Guggenheim), and the Street-low is $4.00 (Mizuho). The average of all 6 active-firm targets is $7.17.
How many active Wall Street firms cover NMRA?+
7 active firms have a recognized rating on Neumora Therapeutics, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NMRA?+
Among analysts who currently cover NMRA, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $14.00 target.
What is Neumora Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.20 – $-0.13) across 7 analysts. Full-year EPS is projected at $-0.86, rising to $-0.61 the following year.
How much revenue is Neumora Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NMRA lately?+
As of Nov 19, 2026, 7 of 7 active firms rate NMRA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NMRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.